Eris Lifesciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Eris Lifesciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹39 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 98% of Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 15% of its market value (net debt). Lower than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹153Over the last 3 years, every ₹100 of reported profit came with ₹153 of operating cash.
Higher than 70% of Healthcare companies in India.
Self-Funding Ratio
3.6×Over the last 3 years its own operating cash covered its investment spending (capex) 3.6 times.
Higher than 84% of Healthcare companies in India.
Cash Locked Ratio
₹17For every ₹100 of sales, ₹17 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹17 tied up three years earlier.
Less money tied up than 65% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹16Sales grew 87% in 3 years; of every extra ₹100 of sales, ₹16 became extra profit.
Higher than 50% of Healthcare companies in India.
Asset Productivity Ratio
+87% / +101%In 3 years sales changed by +87% while total assets changed by +101%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Lower than 75% of Healthcare companies in India.
Cash Cushion Ratio
−15%Debt, after subtracting cash, equals 15% of its market value (net debt).
Lower than 86% of Healthcare companies in India.
Tangible Assets Ratio
39%Of every ₹100 the company owns, ₹39 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Eris Lifesciences Limited owes ₹0.47 for every ₹1 it owns. Net profit rose 76% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
23.9Investors pay ₹23.9 for every ₹1 of Eris Lifesciences Limited's yearly profit, lower than 75% of Healthcare companies in India.
P/B ratio
3.99The share price is 3.99 times Eris Lifesciences Limited's book value per share, lower than 60% of Healthcare companies in India.
Market cap
₹15,555 CrThe total market value of all of Eris Lifesciences Limited's shares at today's price (share price × number of shares), larger than 74% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,903 CrWhat Eris Lifesciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹281.30Net worth divided by the number of shares. The share price of ₹1,121 is 4.0 times this, which is the P/B above.
Return on equity (ROE)
16.4%Eris Lifesciences Limited earned 16.4% on its shareholders' money over the last year, higher than 63% of Healthcare companies in India.
Owes vs Owns
0.47×Eris Lifesciences Limited owes ₹0.47 for every ₹1 it owns (low), higher than 77% of Healthcare companies in India.
Dividend yield
1.29%Eris Lifesciences Limited pays 1.29% of its share price as dividends a year, higher than 86% of dividend-paying Healthcare companies in India.
Revenue growth
+8%Revenue rose 8% in the year to Mar 2026, and grew 23% a year on average over 3 years.
Profit growth
+76%Net profit rose 76% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit margin
19.9%Eris Lifesciences Limited keeps ₹20 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from Eris Lifesciences Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
4.4×Eris Lifesciences Limited's operating profit covered its interest costs 4.4 times in the year to Mar 2026.
Cash vs debt
Net debtEris Lifesciences Limited had ₹2,303 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Eris Lifesciences Limited's P/E ratio?
Investors pay ₹23.9 for every ₹1 of Eris Lifesciences Limited's yearly profit, lower than 75% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Eris Lifesciences Limited: ₹15,555 Cr ÷ ₹3,903 Cr (31 Mar 2026) = 4.0.
What is Eris Lifesciences Limited's return on equity?
Eris Lifesciences Limited earned 16.4% on its shareholders' money over the last year, higher than 63% of Healthcare companies in India.
How much does Eris Lifesciences Limited owe compared with what it owns?
Eris Lifesciences Limited owes ₹0.47 for every ₹1 it owns (low), higher than 77% of Healthcare companies in India.
Does Eris Lifesciences Limited pay a dividend?
Yes. Eris Lifesciences Limited pays 1.29% of its share price as dividends a year, higher than 86% of dividend-paying Healthcare companies in India.
Is Eris Lifesciences Limited's revenue growing?
Revenue rose 8% in the year to Mar 2026, and grew 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.